Abtahi S, Driessen JHM, Burden AM, et al. - This study was undertaken to explore the relationship between concomitant use of oral glucocorticoids (GCs) and proton pump inhibitors (PPIs) and the risk of osteoporotic fractures among patients with rheumatoid arthritis (RA). Researchers conducted a cohort study including patients with RA aged 50+ years from the Clinical Practice Research Datalink between 1997 and 2017. They calculated the risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis, and ribs) by time-dependent Cox proportional-hazards models, statistically adjusted for lifestyle parameters, comorbidities, and comedications. In this study, 1,411 osteoporotic fractures occurred among 12,351 patients with RA (mean age of 68 years, 69% women). The results revealed an interaction in the risk of osteoporotic fractures with concomitant use of oral GCs and PPIs. When a patient with RA is co-prescribed oral GCs and PPIs, fracture risk assessment could be considered.